- Home
- TAVI vs ZNTL Comparison
TAVI vs ZNTL Comparison
Compare TAVI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAVI
- ZNTL
- Stock Information
- Founded
- TAVI 2024
- ZNTL 2014
- Country
- TAVI United Kingdom
- ZNTL United States
- Employees
- TAVI N/A
- ZNTL N/A
- Industry
- TAVI
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- TAVI
- ZNTL Health Care
- Exchange
- TAVI Nasdaq
- ZNTL Nasdaq
- Market Cap
- TAVI 158.5M
- ZNTL 134.7M
- IPO Year
- TAVI 2024
- ZNTL 2020
- Fundamental
- Price
- TAVI $10.00
- ZNTL $2.32
- Analyst Decision
- TAVI
- ZNTL Buy
- Analyst Count
- TAVI 0
- ZNTL 8
- Target Price
- TAVI N/A
- ZNTL $8.53
- AVG Volume (30 Days)
- TAVI 8.6K
- ZNTL 2.7M
- Earning Date
- TAVI 01-01-0001
- ZNTL 03-04-2025
- Dividend Yield
- TAVI N/A
- ZNTL N/A
- EPS Growth
- TAVI N/A
- ZNTL N/A
- EPS
- TAVI N/A
- ZNTL N/A
- Revenue
- TAVI N/A
- ZNTL $40,560,000.00
- Revenue This Year
- TAVI N/A
- ZNTL N/A
- Revenue Next Year
- TAVI N/A
- ZNTL N/A
- P/E Ratio
- TAVI N/A
- ZNTL N/A
- Revenue Growth
- TAVI N/A
- ZNTL N/A
- 52 Week Low
- TAVI $9.99
- ZNTL $1.61
- 52 Week High
- TAVI $10.76
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- TAVI N/A
- ZNTL 49.24
- Support Level
- TAVI N/A
- ZNTL $2.37
- Resistance Level
- TAVI N/A
- ZNTL $2.36
- Average True Range (ATR)
- TAVI 0.00
- ZNTL 0.25
- MACD
- TAVI 0.00
- ZNTL 0.08
- Stochastic Oscillator
- TAVI 0.00
- ZNTL 69.27
About TAVI Tavia Acquisition Corp. Ordinary Shares
Tavia Acquisition Corp is a blank check company.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.